Variation in US commercial health plan coverage restrictions for cell and gene therapies

JAMA

2025-09-29

(Press-News.org) About The Study: For Food and Drug Administration (FDA)-approved cell and gene therapies, commercial health plans commonly imposed coverage requirements beyond FDA-approved product labeling. These restrictions were often aligned with pivotal trial criteria, suggesting that plan coverage aligns with stronger supporting evidence.

Corresponding Author: To contact the corresponding author, James D. Chambers, PhD, email james.chambers@tuftsmedicine.org.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2025.15148)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15148?guestAccessKey=ec35a0f8-f298-4c4b-b6b6-080a7ea92448&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092925

END

ELSE PRESS RELEASES FROM THIS DATE:

Motivational and mobile-based support improved child passenger safety behaviors, clinical trial finds

2025-09-29

Parents improved use of appropriate child car seats after remote motivational counseling and mobile-based support, according to the results from a randomized clinical trial published in JAMA Network Open. The intervention included tailored web content, periodic text messages and personalized feedback on photos parents submitted every four to six weeks showing how their child usually travels in a car. “Parents and children might resist using the recommended car seat or booster seat, even though it’s the law, due to inconvenience or beliefs that their child is safe enough riding ...

Population-level effectiveness and herd protection 17 years after HPV vaccine introduction

2025-09-29

About The Study: In this study, population-level effectiveness and herd protection were robust 17 years after human papillomavirus (HPV) vaccine introduction, even in sexually experienced adolescent girls and young women at relatively high risk for HPV who may not have received the full vaccination series. Corresponding Author: To contact the corresponding author, Jessica Kahn, MD, MPH, email jessica.kahn@einsteinmed.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamapediatrics.2025.3568) Editor’s Note: Please see the article for additional ...

Modeling the health impact of discontinuing COVID-19 vaccination during pregnancy in the US

2025-09-29

About The Study: This decision analytical model study estimates that COVID-19 vaccination (primarily annual COVID-19 vaccination) during pregnancy will likely continue to yield meaningful public health benefits in the U.S., especially to reduce COVID-19 hospitalizations in infants. COVID-19 vaccination during pregnancy has been shown to be safe. While there is global variation in policy recommending COVID-19 vaccination during pregnancy, the U.S. has a high risk of severe COVID-19 in newborns, underscoring relevance of maternal COVID-19 vaccination. Corresponding ...

The rise in early-onset cancer in the US population— more apparent than real

2025-09-29

About The Study: The rise in early-onset cancer incidence does not consistently signal a rise in the occurrence of clinically meaningful cancer. While some of the increase in early-onset cancer is likely clinically meaningful, it appears small and limited to a few cancer sites. Much of the increase appears to reflect increased diagnostic scrutiny and over-diagnosis. Interpreting rising incidence as an epidemic of disease may lead to unnecessary screening and treatment while also diverting attention from other more pressing health threats in young adults. Corresponding Author: To contact the corresponding author, H. Gilbert Welch, MD, MPH, email drgilwelch@gmail.com. To ...

Scientists reveal functional RNA splitting mechanism behind origin of Type V CRISPR systems

2025-09-29

CRISPR-Cas systems are adaptive immune systems found in prokaryotes that defend against invading nucleic acids through CRISPR RNA-guided cleavage. Type V CRISPR-Cas (Cas12) systems, in particular, serve as one of today’s most powerful tools for genome editing, especially in basic research, medicine, and agriculture. Researchers led by Prof. GAO Caixia from the Institute of Genetics and Developmental Biology (IGDB) of the Chinese Academy of Sciences (CAS), together with Assoc. Prof. LIU Junjie from Tsinghua University ...

Study shows HPV vaccine protects vaccinated — and unvaccinated — women

2025-09-29

September 29, 2025 (BRONX, NY)—A large, long-term study led by an Albert Einstein College of Medicine researcher has found that the introduction of the human papillomavirus (HPV) vaccine in community settings is highly effective in protecting young women from infections caused by the cervical-cancer-causing virus—including women who didn’t even receive the vaccine. The study was published today in JAMA Pediatrics. “There are two encouraging takeaways from our study,” said lead ...

Childhood overeating can be a harbinger of later mental health struggles in girls, study finds

2025-09-29

Girls who overeat regularly in the preschool years are more likely to experience anxiety, impulsivity and hyperactivity in adolescence, according to a new study led by researchers at McGill University and the Douglas Research Centre. The study followed more than 2,000 Quebec children using provincial data, tracking eating patterns reported by caregivers in early childhood and assessing mental-health symptoms when participants turned 15. The link between overeating and later difficulties was seen in girls, but not in boys. Takeaway for caregivers The findings ...

Over 99% have a risk factor before heart attack, stroke or heart failure

2025-09-29

One or more risk factors above optimal levels — high blood pressure, cholesterol, glucose or smoking — almost always precedes a cardiac event Findings refute the commonly held belief that heart disease often strikes people without warning Authors urge greater attention to early detection and control of these modifiable risks CHICAGO --- More than 99% of people who went on to suffer a heart attack, stroke or heart failure already had at least one risk factor above optimal level beforehand, ...

American College of Cardiology issues scientific statement on inflammation and cardiovascular disease

2025-09-29

WASHINGTON (September 29, 2025) — The American College of Cardiology (ACC) released today its second Scientific Statement, Inflammation and Cardiovascular Disease (CVD). The statement emphasizes years of clinical and basic science research, confirming that inflammation is an important underlying contributor to several CVDs, including coronary artery disease and heart failure. Key Points: High-sensitivity C-reactive protein (hsCRP) is an inexpensive and widely available blood test. While there has been debate within the medical community regarding the utility of hsCRP, this statement details the data confirming its ...

Multi-omics machine learning can detect ALS 10 years before symptom appears

2025-09-29

A new study applying multi-omics techniques and machine learning identified 33 plasma proteins that differ significantly in patients with amyotrophic lateral sclerosis (ALS). The findings suggest ALS could be detected up to 10 years before symptoms appear, offering promise for reliable diagnostic biomarkers. The integration of advanced high-throughput sequencing technologies, such as whole genome sequencing (WGS) for the early detection of rare diseases, such as ALS, could give clinicians and patients a critical window for ...

LAST 30 PRESS RELEASES:

Quality and quantity? The clinical significance of myosteatosis in various liver diseases

Expert consensus on clinical applications of fecal microbiota transplantation for chronic liver disease (2025 edition)

Insilico Medicine to present three abstracts at the 2026 Crohn’s & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411, a novel gut-restricted PHD1/2 inhibitor fo

A cigarette compound-induced tumor microenvironment promotes sorafenib resistance in hepatocellular carcinoma via the 14-3-3η-modified tumor-associated proteome